Company* |
University/ |
Type Of Agreement |
Product Area |
Details (Date) |
| | ||||
Aclara BioSciences Inc. (ACLA) Laboratory |
Lawrence Livermore National |
Service and supply agreement |
To provide access to Aclara's eTag Assay System to develop rapid detection assays for biological agents |
The agreement includes supply of eTag assay reagent products, software and services (4/8) |
|
|
|||
Aclara BioSciences Inc. (ACLA) |
University of Southern California's Norris Comprehensive Cancer Center and Hospital |
Partnership |
To identify and characterize clinical biomarkers for cancer |
The parties will apply Aclara's multiplexed eTag Assay System to discover breast cancer biomarkers (4/16) |
|
||||
Adherex Technologies Inc. (Canada; TSE:AHX) |
National Cancer Institute |
Screening agreement |
To evaluate the anti-cancer effects and vascular-targeting capabilities of compounds from Adherex's library of cadherin antagonists |
The classes of agents to be included under the agreement include peptidecadherin antagonist compounds for N-cadherin, E-cadherin, desmogleins, VE-cadherin and OB-cadherin, as well as Adherex's non-peptide cadherin antagonists (5/13) |
|
||||
Advanced Biosystems Inc. (subsidiary of Analex Corp.; AMEX:NLX) |
Defense Advanced Research Projects Agency |
Contract |
To develop capabilities and techniques for use in creating and evaluating surrogate lung tissues and their suitability as tools in the study of infection |
The 10-month contract is worth about $2M for Advanced Biosystems (5/1) |
|
|
|||
A.I. Software Inc.* (Canada) |
Technion University of Israel and the Weizmann Institute (Israel) |
Licensing agreement |
For a stem cell expansion technology |
The company will develop a process to assist with bone marrow transplants (4/24) |
|
|
|||
Althea Technologies Inc.* |
National Institutes of Health |
Four-year contract |
To assist the National Institute of Allergy and Infectious Diseases with the development, scaleup and production of candidate vaccines |
The contract also calls for Althea to perform the necessary characterization tests required for release of vaccines for clinical use (4/15) |
|
|
|||
Applied Imaging Corp. (AICX) |
Wellcome Trust Sanger Institute (UK) |
Agreement |
For Applied Imaging to be sole imaging development partner in Sanger's Atlas of Gene Expression project |
Applied Imaging will develop applications for high-throughput analysis of tissue samples using its Ariol software; Applied Imaging will have exclusive worldwide commercial rights to sell the various Ariol applications developed under the agreement (4/29) |
|
||||
Arius Research Inc. (Canada; VSE:YAR) models of human ovarian cancer |
Ottawa Regional Cancer Centre (Canada) |
Collaboration |
To study a group of cancer-killing antibodies in specialized |
ORCC will test the antibodies in its models for drug efficacy (5/1) |
|
|
|||
Astex Technology Ltd.* |
Institute of Cancer Research Technology (UK) |
Exclusive agreement enzyme protein |
For the discovery of drugs against the and develop drug candidates for kinase B |
Astex and the institute established a joint research team to identify (UK) indications in the oncology area (3/20) |
|
|
|||
Biosyn Inc.* |
National Institutes of Health |
Exclusive worldwide rights agreement |
To develop and commercialize a protein called cyanovirin-N as an HIV microbicide |
Further details were not disclosed (4/3) |
|
|
|||
BioVex Ltd.* (UK) |
Vaccine Research Center at the National Institute of Allergy and Infectious Diseases |
Agreement |
To develop an HIV vaccine using BioVex's ImmunoVEX herpes simplex-based platform |
The vaccine would incorporate a combination of VRC's HIV antigen genes aimed at maximizing the immune response to the virus (5/12) |
|
|
|||
Carrington Laboratories Inc. (CARN) |
Southern Research Institute |
Agreement |
To develop a platform to improve sustained delivery of therapeutic proteins and peptides |
The agreement is for five years (5/1) |
|
||||
Cellomics Inc.* |
Mayo Clinic and Foundation |
Collaboration |
To provide access to Cellomics' range of products, including the Array-Scan HCS Reader, the KineticScan HCS Reader, the vHCS Discovery ToolBox and the line of Bio-Application software modules for automated cell analyses |
Financial details were not disclosed (4/30) |
|
|
|||
CombiMatrix Corp. (CBMX) |
Nihon Gene Research Laboratory (Japan) |
Agreement |
To sell a DNA Micro-array Synthesizer |
NGRL will supply the Japanese market with a custom microarray production and analysis service; the two parties also entered an agreement to investigate various aspects of genetic analysis (4/7) |
|
||||
|
Commonwealth Biotechnologies Inc. (CBTE)
|
National Institute of Justice |
Purchase agreement |
For performance of DNA genotyping work associated with convicted offenders |
The agreement is for April 1, 2003, through March 31, 2004, and is valued at $25M (5/5) |
|
|
|||
Cyclacel Ltd.* (UK) |
Cancer Research Technology Ltd. and the University of Cambridge (UK) |
Collaboration |
To develop RNA interference technology for target validation and drug discovery |
The parties have combined intellectual property; collaboration is aimed at improving RNAi technology in mammalian cells to allow the generation of new disease models and systems for analyzing mammalian gene expression (3/31) |
|
||||
CytRx Corp. |
University of Massachusetts Medical School |
Licensing agreements |
For a portfolio of applications for gene silencing technology in the areas of Type II diabetes, obesity and cancer |
CytRx is giving up 1.6M shares in the agreement (4/21) |
|
||||
DelSite Biotechnologies Inc. (subsidiary of Carrington Laboratories Inc.; CARN) |
University of Southern Mississippi of protein and peptide therapeutics |
Agreement |
To develop water-soluble polymer technology for the controlled release |
The program will operate under the direction of the school's department of polymer science (5/6) |
|
||||
DiaDexus Inc.* |
Mayo Medical Laboratories |
Agreement |
To provide analyte-specific reagents to Mayo |
Mayo will use the reagents to develop a test for the quantitative measurement of lipoprotein-associated phospholipase A2 in blood (3/28) |
|
||||
Diversa Corp. (DVSA) |
U.S. Department of Energy's Joint Genome Institute |
Collaboration |
To discover and sequence microbial genomes found in arange of habitats |
Diversa will use its technologies to extract DNA from environmental samples and make gene libraries, while JGI will perform DNA sequencing (5/5) |
|
|
|||
Domantis Ltd.* |
UK Medical Research Council (UK) |
Agreement |
For exclusive access to a novel polymerase technology, which will accelerate the discovery of polypeptides, including the domain antibodies in which Domantis specializes |
The aim is to create a “polymerase engine," enabling Domantis to select polypeptides with improved properties; the company also will license the technique to reagent and diagnostic companies that want to access new polymerases (4/16) |
|
||||
DOR BioPharma |
Thomas Jefferson University |
Exclusive worldwide license agreement |
For an intellectual property portfolio related to development of vaccines to combat intoxication by botulinum toxin |
More than $2.1M of grant support from the National Institutes of Health was invested in developing the vaccine candidates and related work on the mechanisms of botulinum toxin (5/7) |
|
||||
Elixir Pharmaceuticals Inc.* |
National Human Genome Research Institute and University of Michigan |
Collaboration |
To study the relationship of the Lamin A gene to the normal the aging process |
Further details were not disclosed (4/25) |
|
|
|||
Exact Sciences Corp. (EXAS) |
Johns Hopkins Kimmel Cancer Center |
Licensing agreement |
For the cancer center's digital PCR technology |
The technology could lead to the development of colorectal cancer screening and detection technologies that may enhance Exact Sciences' PreGen-Plus assay (4/24) |
|
||||
Genaissance Pharmaceuticals Inc. (GNSC) |
Wayne State University |
Agreement |
To support the university's research contract with the National Institute of Child Health and Human Development's Perinatology Research Branch |
The university will gain access to specific HAP markers and receive a limited license to use Genaissance's DecoGen Informatics System; Genaissance will develop assays for the selected HAP markers and provide high-throughput genotyping on clinical samples; Genaissance will receive a license fee and other payments from the university (3/25) |
|
|
|
||
Genedata AG* (Switzerland) |
National Cancer Center (Japan) |
Research collaboration |
To identify minimal sets of diagnostic marker proteins decisive for delineating cancer types into subclasses |
Genedata licensed its Impressionist product to the National Cancer Center, which will use it in conjunction with 2D-protein gel data derived from Ettan DIGE technology from Amersham Biosciences (5/12) |
|
||||
GenVec Inc. |
National Institutes of Health |
Agreement |
To develop a vaccine for severe acute respiratory syndrome (SARS) |
The government will be in charge of testing the vaccine candidate in preclinical models to assess safety and efficacy, after which clinical trials may start (4/25) |
|
|
|||
Hemispherx Biopharma Inc. (AMEX:HEB) |
Center for Cell and Gene Therapy at Baylor College of Medicine |
Agreement |
For work conducted using the Phase III drug Ampligen in the implementation of the protocol titled “Administration of neomycin resistance gene-marked LMP2a-specific CTL to patients with relapsed EBV-positive Hodgkin's lymphoma" |
Hemispherx will provide Ampligen and Baylor College will conduct and fund the research (5/5) |
|
|
|||
Hemispherx Biopharma Inc.(AMEX:HEB) |
Genome Institute (Singapore) |
Research collaboration |
To test its lead products in treating severe acute respiratory syndrome (SARS) |
Hemispherx plans to test its Alferon N product and Ampligen (5/13) |
|
||||
Iconix Pharmaceuticals Inc.* |
University of California at Berkeley |
Licensing agreement |
For exclusive rights to data-mining tools for experiments in predictive chemo-genomics |
Iconix will apply data-mining tools created by Laurent El Ghaoui of the university to develop additional drug signatures (4/23) |
|
|
|||
IGEN International Inc. (IGEN) |
Food Safety and Inspection Service of the U.S. Department of Agriculture |
Purchase agreement |
For IGEN's botulinum toxin test |
The service will use the test as part of an expansion of its Homeland Security program for food safety (4/21) |
|
||||
IGEN International Inc. (IGEN) |
U.S. Air Force |
Agreement |
For the detection of biological agents in order to protect military personnel |
The products are based on IGEN's Origen technology and are able to detect select biological agents within 30 minutes (3/20) |
|
|
|||
Immucor Inc. (BLUD) and Bio-Tek Instruments Inc.* |
University of Vermont |
Agreement |
To commercialize an in vitro diagnostic test to measure platelet markers used in antiplatelet pharmacological drug development and to potentially improve real-time treatment of cardiovascular disease |
The assay is expected to be used in determining the risk associated with increased platelet activity and decreased reactivity (4/30) |
|
||||
Ingenium Pharmaceuticals AG* (Germany) |
Molecular Genetics Laboratory of the University Eye Hospital (Germany) |
Collaboration |
For Ingenium to use its INGENOtyping technology platform to develop animal models with defined gene alterations |
The collaboration is focused on genes relating to eye diseases (4/16) |
|
||||
Ingenuity Systems Inc.* |
ABC2 and CaP CURE |
Partnership |
To test existing chemotherapeutic agents against recently discovered gene defects associated with prostate and brain cancer pathways |
Financial terms were not disclosed (4/1) |
|
|
|||
Introgen Therapeutics Inc. (INGN) |
The University of Texas M.D. Anderson Cancer Center |
Exclusive worldwide license agreement |
For the fus1 gene |
The gene is believed to inhibit the growth of tumors and reduce the spread of lung cancer in animals; Introgen gained rights to the gene (5/1) |
|
||||
LaunchCyte LLC* |
University of Pittsburgh |
Exclusive option agreement |
For LaunchCyte to license a platelet non-adhesion technology |
LaunchCyte will evaluate the technology while developing commercialization and funding strategies toward the creation of a new venture (4/10) |
|
|
|||
Lincoln |
FDA |
Cooperative research and development agreement |
To develop data-mining tools to assess drug safety |
Further details were not disclosed (5/2) |
|
|
|||
Lynx Therapeutics Inc. (LYNX) |
Institute for Systems Biology |
Service agreement |
To study prostate cancer gene expression using Lynx's Massively Parallel Signature Sequencing technology |
Lynx will receive payments for the genomics discovery services it performs on samples provided by the institute (5/14) |
|
|
|||
Lynx Therapeutics Inc. (LYNX) |
National Institute on Aging |
Service agreement |
To study stem cell gene expression using Lynx's Massively Parallel Signature Sequencing technology |
Lynx will receive payments for the genomics discovery services it performs on samples provided by the NIA (5/7) |
|
||||
Lynx Therapeutics Inc. (LYNX) |
Northeastern University |
Service agreement |
To study the regulation of gene expression in Antarctic icefish using Lynx's Massively Parallel Signature Sequencing technology |
Lynx will receive payments for the genomic discovery services it performs on the samples provided (4/10) |
|
|
|||
Medarex Inc. (MEDX) |
Massachusetts Biologic Laboratories of the University of Massachusetts Medical School |
Agreement |
For Medarex to use its UltiMAb technology to develop fully human antibodies to severe acute respiratory syndrome (SARS) |
The parties will share equally the development costs of any antibody products as well as any future revenues (4/25) |
|
|
|||
Microfluidic Systems Inc.* |
Defense Advanced Research Projects Agency |
Contract |
To build an airborne pathogen detection and identification system |
Microfluidic Systems received the contract for $1.5M as part of a collaboration with the Lawrence Livermore National Laboratory (3/20) |
|
|
|||
Morphochem AG* (Germany) |
German Research Center for Biotechnology (Germany) |
Agreement |
To apply Morphochem's MOREsystem drug discovery engine to develop cancer therapeutics using tubulysins |
Morphochem gained exclusive access to the center's research results on the natural substance class of small peptides isolated from myxobacteria; Morpho- chem will fund the research and will pay license fees if a therapeutic reaches the market (3/24) |
|
||||
NaPro BioTherapeutics Inc.(NPRO) |
University of Texas M.D. Anderson Cancer Center |
Exclusive licensing agreement |
For worldwide rights to HN-1 peptide delivery technology |
NaPro will provide the institution royalties and funding for further research (3/27) |
|
|
|||
Neurotech SA* (France) |
INSERM, the French National Institute of Health for Medical Research (France) |
Agreement |
To study interactions between the pigment epithelium and the neuronal retina and other vessels |
INSERM will apply its high-throughput screening to identify genes expressed by the pigment retinal epithelium and implicated in retinal diseases (3/24) |
|
||||
Nexia Biotechnologies Inc. (Canada; TSE:NXB) |
Defence R&D Canada-Suffield (Canada) |
Agreement |
To research and test Protexia, a protein designed to protect people against the toxic effects of nerve gas and other organophosphate agents |
Protexia is Nexia's recombinant version of butyrylcholinesterase (3/31) |
|
||||
Nexia Biotechnologies Inc. (Canada; TSE:NXB) |
U.S. Army Medical Research Materiel Command |
Research contract |
To develop Protexia, Nexia's recombinant form of butyrylcholin-esterase |
Nexia was awarded the C$3.94M (US$2.67M) research contract (4/4) |
|
||||
Paradigm Genetics Inc. (PDGM) |
National Institute of Environmental Health Sciences |
Exercised option |
For an additional $8.4M for toxico-genomics studies |
Data generated from the research will help in better understanding the short- and long-term exposures to chemicals (4/24) |
|
|
|||
Phase-1 Molecular Technology Inc.* |
National Cancer Institute |
Agreement |
For Phase-1 to provide toxicogenomics services to NCI |
The service will provide insights into cancer treatments and the toxicity produced by those agents in comparison to the mechanism of antitumor action (5/6) |
|
||||
Pure Protein LLC* |
National Institutes of Health |
Licensing agreement |
For the NIH's three hepatitis C-transfected cell lines to use in Pure-Protein's vaccine discovery project |
Promising targets will be licensed to vaccine and drug designers (4/21) |
|
|
|||
Pyrosequencing AB (Sweden; SSE:PYRO) |
Thomas Jefferson University |
Sponsored research agreement |
To analyze genes and develop applications for inflammatory bowel disease |
The university recently purchased a PSQ HS 96A system, Pyrosequencing's genotyping platform, to advance clinical mol ecular genetics research, including in inflammatory bowel disease (3/31) |
|
||||
Repligen Corp. (RGEN) |
Boston University Medical Center |
Collaboration |
To evaluate three approaches to quantifying changes in the symptoms of autism |
Cure Autism Now awarded three grants to fund the development of new tools to quantify changes in the symptoms of autism in clinical trials (5/14) |
|
||||
Revotar Biopharmaceuticals AG* (Germany) |
Department of Molecular Cardiology of the University Hospital RWTH Aachen (Germany) |
Collaboration |
For junctional adhesion molecule-1 |
Financial terms were not disclosed (5/5) |
|
|
|||
Targeted Genetics Corp. (TGEN) |
Cystic Fibrosis Foundation Therapeutics Inc. |
Agreement |
To advance the development of Targeted Genetics' product, tgAAVCF, to treat patients with cystic fibrosis |
The focus of the collaboration is to conduct a Phase IIb trial to evaluate the efficacy of tgAAVCF in patients with mild to moderate CF (4/24) |
|
|
|
||
Valent BioSciences Corp.* (Canada) |
National Research Council of Canada's Plant Biotechnology Institute
|
Exclusive research partnership |
To investigate agricultural applications of synthetic analogues of abscisic acid |
Valent gains the first option to license the institute's technology for commercial development on a worldwide basis (5/6) |
|
|
|||
Vical Inc. (VICL) |
Vaccine Research Center of the National Institute of Allergy and Infectious Diseases |
Manufacturing contract agreement |
To manufacture bulk DNA vaccines |
The VRC will underwrite the capital for a 500-liter fermenter and related purification equipment in Vical's new manufacturing facility (5/12) |
|
||||
ViroLogic Inc. (VLGC) |
International AIDS Vaccine Initiative |
Collaboration |
To develop vaccines against HIV/AIDS |
ViroLogic's PhenoSense HIV antibody-neutralization assay will be used in IAVI-sponsored preclinical and clinical research studies evaluating HIV vaccine candidates (3/28) |
|
||||
|
| ||||
Notes: | ||||
This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AMEX = American Stock Exchange; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange | ||||
